Although investors could benefit from reading the entire book, we've selected a bite-sized sampling of the tips and suggestions regarding the investor mindset and ways to improve stock selection that will help you get inside Buffett's head.
1. Think of Stocks as a Business
Many investors think of stocks and the stock market in general as nothing more than little pieces of paper being traded back and forth among investors. This might help prevent investors from becoming too emotional over a given position, but it doesn't necessarily allow them to make the best possible investment decisions.
Best Low Price Stocks To Buy For 2015: ATMI Inc.(ATMI)
ATMI, Inc. supplies high performance materials, materials packaging, and materials delivery systems for use in the manufacture of microelectronics devices worldwide. The company primarily offers front-end semiconductor performance materials; sub-atmospheric pressure gas delivery systems for safe handling and delivery of toxic and hazardous gases to semiconductor process equipment; and high-purity materials packaging and dispensing systems that allow for the reliable introduction of low volatility liquids and solids to microelectronics and biopharmaceutical processes. It also provides containment, mixing, and bioreactor technologies to the biotechnology, laboratory, and cell therapy markets. The company serves semiconductor and flat-panel display manufacturers, as well as the life sciences industry. It has strategic alliances with Enthone, Inc. and Lake LED Materials, Co., Ltd. The company was founded in 1986 and is headquartered in Danbury, Connecticut.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
ATMI (NASDAQ: ATMI) shot up 25.51 percent to $33.80 after the company reported upbeat Q4 earnings. Entegris (NASDAQ: ENTG) announced its plans to acquire ATMI.
Top 5 Warren Buffett Stocks To Buy For 2014: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 - a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line treatment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
Advisors' Opinion:- [By James E. Brumley]
Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.
- [By John Udovich]
On Wednesday, small cap cancer stock Clovis Oncology Inc (NASDAQ: CLVS) soared 16.68% after announcing a $200 million cancer deal plus the biotech has more than tripled since late 2011, meaning it might be time to take a closer look at what�� driving the stock higher as well as look at the performance of biotech ETF benchmarks like iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By Sean Williams]
What: Shares of Clovis Oncology (NASDAQ: CLVS ) , a biopharmaceutical company that's developing anti-cancer therapies, vaulted higher by as much as 136% (that's not a typo!) after reporting positive data on two early stage experimental treatments -- CO-1686 in EGFR-mutant non-small cell lung cancer (NSCLC) and Rucaparib in a monotherapy study of solid tumors -- at the American Society of Clinical Oncology's annual meeting.
Top 5 Warren Buffett Stocks To Buy For 2014: Amazonica Corp (AMZZ)
Amazonica, Corp., incorporated on February 6, 2010, is a development-stage company. The Company is engaged in the field of marketing and distributing hardwood flooring and other construction materials.
The Company is a distributor of Brazilian hardwood flooring. Brazilian hardwood is manufactured from rare types of wood, such as Rose Wood, Snake Wood, Brazilian Teak, Santos Mahogany, Tigerwood, Brazilian Walnut and others. As of August 13, 2013, the Company had no revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Banjo & Matilda, Inc (OTCMKTS: BANJ), Amazonica Corp (OTCBB: AMZZ) and Guardian 8 Holdings (OTCMKTS: GRDH) have been getting some extra attention in various investment newsletters or email alerts. Of course, there is nothing wrong with properly disclosed promotion or investor relations type of activities but they can cause problems for unwary investors and traders alike. So how hot are these three small cap stocks? Here is a closer look and a reality check:
Top 5 Warren Buffett Stocks To Buy For 2014: UC Resources Ltd (UC&C)
UC Resources Ltd. is an exploration-stage company. The Company is engaged principally in the acquisition, exploration and development of mineral properties in Mexico. The Company focuses on silver and gold exploration and production in Mexico. Its mineral properties include Copalquin property (Copalquin Project) and La Yesca. Its Copalquin is located in the northwestern state corner of Durango State, in Mexico. La Yesca is 100% owned by the Company�� subsidiary, Minera Silver Creeck. The La Yesca milling project is located near the town of La Yesca in Nayarit, Mexico, approximately 100 kilometers northwest of Guadalajara City. In the La Yesca district there are at least 16 known gold and silver mineral discoveries. The Mar project consists of a 100 hectare mining exploitation concession. On September 6, 2012, the Company discovered another previously unknown existing mine prospect on the La Yesca property just North of La Leona Mine. Advisors' Opinion:- [By Victor Selva]
Polycom provides standards-based unified communications and collaboration (UC&C) solutions for voice and video collaboration. The company has three products and solutions categorized as follows: UC Platform, UC Group Systems and UC Personal Devices.
No comments:
Post a Comment